Intravenous iron infusion as an alternative to minimize blood transfusion in peri-operative patients

• Published in: Scientific reports Vol. 10; no. 1; p. 18403
• Main Authors: Ionescu, Alin, Sharma, Abhinav, Kundnani, Nilima Rajpal, Mihăilescu, Alexandra, David, Vlad Laurențiu, Bedreag, Ovidiu, Săndesc, Dorel, Dinu, Anca Raluca, Săndesc, Mihai Alexandru, Albulescu, Nicolae, Drăgoi, Răzvan Gabriel
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27-10-2020; Nature Publishing Group
• Subjects: 692/308; 692/700; Anemia, Iron-Deficiency - blood; Anemia, Iron-Deficiency - therapy; Blood Transfusion; Blood transfusions; Dietary supplements; Female; Humanities and Social Sciences; Humans; Infusions, Intravenous; Intravenous administration; Iron; Iron - administration & dosage; Iron deficiency; Male; multidisciplinary; Nutrient deficiency; Patients; Perioperative Period; Retrospective Studies; Science; Science (multidisciplinary); Surgery; Transfusion
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-75535-2

Despite the reported benefits of intravenous iron therapy (IVIT) for correcting iron deficiency anemia (IDA) before any major surgery and the evidence thereof, perioperative allogenic blood transfusion (ABT) practice is still considered as the only viable option by some clinicians worldwide. As ABT increases the likelihood of infections, cardiac complications, longer hospital stays and mortality among the patients, the practice of ABT should only be reserved for critical cases (Hb level < 7 g/dl). Timely iron studies and iron replenishment (oral/IV) of prospective surgical patients could help decrease the ABT practice, and prove beneficial from both the clinical and economic standpoint. Evidence based patient blood management guidelines should be developed and standardized for use by clinicians worldwide. These guidelines should include specific instructions on timely assessment of surgical patients for correction of their IDA by either oral iron supplementation, if time permits, or by using IVIT such as ferric carboxymaltose (FCM) in emergency surgeries and in patients with functional ID. This study was conducted to explore the clinical benefits of the timely administration of IV-FCM in iron-deficient preoperative patients during 2017–2018 and compare the results thereof with that of the ABT. Based on the IDA treatment plan of 2953 patients, 11.14% cases were administered IV FCM (Group 1), 11.58% cases received ABT (Group 2), while the remaining 77.27% of anemic cases received neither ABT nor IV FCM (Group 3). The results indicate that the IV FCM administration reduces the need for ABT and thus minimizes its associated side effects. The findings of our study concur with the favorable outcomes reported by the other similar studies.